Literature DB >> 31035796

A Review of Humoral Factors in Remote Preconditioning of the Heart.

Sergey Y Tsibulnikov1, Leonid N Maslov1, Alexander S Gorbunov1, Nikita S Voronkov1, Alla A Boshchenko1, Sergey V Popov1, Ekaterina S Prokudina1, Nirmal Singh2, James M Downey3.   

Abstract

A humoral mechanism of cardioprotection by remote ischemic preconditioning (RIP) has been clearly demonstrated in various models of ischemia-reperfusion including upper and lower extremities, liver, and the mesenteric and renal arteries. A wide range of humoral factors for RIP have been proposed including hydrophobic peptides, opioid peptides, adenosine, prostanoids, endovanilloids, endocannabinoids, calcitonin gene-related peptide, leukotrienes, noradrenaline, adrenomedullin, erythropoietin, apolipoprotein, A-I glucagon-like peptide-1, interleukin 10, stromal cell-derived factor 1, and microRNAs. Virtually, all of the components of ischemic preconditioning's signaling pathway such as nitric oxide synthase, protein kinase C, redox signaling, PI3-kinase/Akt, glycogen synthase kinase β, ERK1/2, mitoKATP channels, Connexin 43, and STAT were all found to play a role. The signaling pattern also depends on which remote vascular bed was subjected to ischemia and on the time between applying the rip and myocardial ischemia occurs. Because there is convincing evidence for many seemingly diverse humoral components in RIP, the most likely explanation is that the overall mechanism is complex like that seen in ischemic preconditioning where multiple components are both in series and in parallel and interact with each other. Inhibition of any single component in the right circumstance may block the resulting protective effect, and selectively activating that component may trigger the protection. Identifying the humoral factors responsible for RIP might be useful in developing drugs that confer RIP's protection in a more comfortable and reliable manner.

Entities:  

Keywords:  heart; humoral factors; ischemia; remote preconditioning; reperfusion

Mesh:

Year:  2019        PMID: 31035796     DOI: 10.1177/1074248419841632

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  6 in total

Review 1.  Controlling Reperfusion Injury With Controlled Reperfusion: Historical Perspectives and New Paradigms.

Authors:  Demetria M Fischesser; Bin Bo; Rachel P Benton; Haili Su; Newsha Jahanpanah; Kevin J Haworth
Journal:  J Cardiovasc Pharmacol Ther       Date:  2021-09-17       Impact factor: 2.457

Review 2.  Remote ischaemic conditioning: defining critical criteria for success-report from the 11th Hatter Cardiovascular Workshop.

Authors:  R M Bell; M Basalay; H E Bøtker; S Beikoghli Kalkhoran; R D Carr; J Cunningham; S M Davidson; T J England; S Giesz; A K Ghosh; P Golforoush; A V Gourine; D J Hausenloy; G Heusch; B Ibanez; P Kleinbongard; S Lecour; K Lukhna; M Ntsekhe; M Ovize; A D Salama; G Vilahur; J M Walker; D M Yellon
Journal:  Basic Res Cardiol       Date:  2022-08-15       Impact factor: 12.416

3.  IcyHot analgesic topical cream limits cardiac injury in rodents.

Authors:  Yun Wu; Annabel W Chen; Candida L Goodnough; Yao Lu; Ye Zhang; Eric R Gross
Journal:  Transl Res       Date:  2020-07-03       Impact factor: 7.012

Review 4.  Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State-New Directions in Anti-Aging Regenerative Therapies.

Authors:  Klaudia Maar; Roland Hetenyi; Szabolcs Maar; Gabor Faskerti; Daniel Hanna; Balint Lippai; Aniko Takatsy; Ildiko Bock-Marquette
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

5.  Exploring the role of neurogenic pathway-linked cholecystokinin release in remote preconditioning-induced cardioprotection.

Authors:  Huilian Li; Cuilan An
Journal:  Acta Cir Bras       Date:  2020-10-30       Impact factor: 1.388

6.  Cardiomyocyte Protection by Hibernating Brown Bear Serum: Toward the Identification of New Protective Molecules Against Myocardial Infarction.

Authors:  Lucas Givre; Claire Crola Da Silva; Jon E Swenson; Jon M Arnemo; Guillemette Gauquelin-Koch; Fabrice Bertile; Etienne Lefai; Ludovic Gomez
Journal:  Front Cardiovasc Med       Date:  2021-07-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.